Ademta powder, lyophilized for preparation of solution for injection, 400 mg 5 vials — Made in Turkey — Free Delivery

Ademta is a preparation that affects the digestive system and metabolic processes. Amino acids and their derivatives.

intrahepatic cholestasis in adults, including patients with chronic hepatitis of various etiologies and liver cirrhosis;

intrahepatic cholestasis in pregnant women;

depressive syndromes.

1 bottle contains ademetionine (in the form of ademetionine 1,4-butanedisulfonate) 400 mg;

excipients: mannitol (E 421);

1 ampoule (5 ml) with solvent contains L-lysine monohydrochloride, sodium hydroxide, water for injection.

Hypersensitivity to the active substance or to any excipient of the preparation.

Genetic defects affecting the methionine cycle and / or causing homocystinuria and / or hyperhomocysteinemia (eg, deficiency of cystathionine beta-synthase, defect in vitamin B12 metabolism).

The preparation is administered intravenously or intramuscularly at a dose of 5-12 mg / kg of body weight per day. The initial dose is 400 mg / day, the total daily dose should not exceed 1000 mg. The duration of initial parenteral therapy is 15-20 days in the treatment of depressive syndromes and 14 days in the treatment of liver diseases.

When using the preparation, the level of ammonia should be monitored in patients with a precirotic or cirrhotic stage of hyperammonemia, who are using ademetionine tablets.

Since vitamin B12 and folate (folate) deficiency can lead to a decrease in ademetionine concentration, patients at risk (anemia, liver disease, pregnancy, or the possibility of developing vitamin deficiency through other diseases or a dietary method, such as vegetarianism) should regularly take the preparation conduct a blood test to check the plasma levels of these substances.

In the course of clinical studies in women taking ademetionine in the third trimester of pregnancy, no adverse reactions were observed. During the I and II trimester of pregnancy, the preparation should be used only after a doctor's careful assessment of the ratio of benefit to the pregnant woman / risk to the fetus.

The safety and efficacy of using ademetionine in children have not been established.

When using ademetionine, dizziness may occur in some patients. In such cases, you should refrain from driving vehicles or other mechanisms until the symptoms disappear completely, which may affect the reaction rate during these activities.

Rarely have been reported cases of overdose with ademetionine. In case of overdose, monitoring of the patient's condition and supportive treatment is recommended.

From the digestive tract: abdominal pain, diarrhea, nausea, dry mouth, dyspepsia, flatulence, gastrointestinal pain, gastrointestinal bleeding, gastrointestinal upset, vomiting, esophagitis, bloating.

General disorders and reactions at the injection site: asthenia, edema, hyperthermia, chills, reactions at the injection site, necrosis at the injection site, malaise.

From the immune system: hypersensitivity, anaphylactoid reactions or anaphylactic reactions (eg, flushing, shortness of breath, bronchospasm, back pain, chest discomfort, changes in blood pressure (arterial hypotension, arterial hypertension) or pulse rate (tachycardia, bradycardia)) ...

Store at a temperature not exceeding 25 ° C, out of the reach of children.

The prepared solution is stable for 6 hours at a temperature not exceeding 25 ° C or for 24 hours at a temperature of 2-8 ° C.